Table 4:
Patient and Tumor Characteristics in Reassigned Treatment Stages
| Characteristic | BCLC Bn (n = 272) | BCLC Cn (n = 222) |
|---|---|---|
|
| ||
| Age (y)* | 61 (55–71) | 62 (56–71) |
| Sex | ||
| M | 220 (80.9) | 181 (81.5) |
| F | 52 (19.1) | 41 (18.5) |
| α-fetoprotein level | ||
| <400 ng/mL | 123 (45.2) | 60 (27.0) |
| ≥400 ng/mL | 38 (14.0) | 58 (26.1) |
| ECOG performance status | ||
| 0 | 149 (54.8) | 56 (25.2) |
| 1 | 112 (41.2) | 155 (69.8) |
| 2 | 11 (4.0) | 11 (5.0) |
| Child-Pugh class | ||
| A | 182 (66.9) | 127 (57.2) |
| B | 90 (33.1) | 95 (42.8) |
| Tumor characteristics | ||
| Tumor multiplicity | ||
| Unifocal | 47 (17.3) | 47 (21.2) |
| Multifocal | 225 (82.7) | 175 (78.8) |
| Extrahepatic metastasis | 24 (8.8) | 50 (22.5) |
| Portal vein invasion | 38 (14.0) | 132 (59.5) |
| Total tumor volume (cm3)* | 79 (26–200) | 733 (298–1461) |
| ETV (cm3)* | 30 (11–59) | 355 (174–696) |
| ETB (%)* | 2 (1–4) | 15 (1–30) |
Note.—Unless otherwise specified, data are numbers of patients, with percentages in parentheses. BCLC = Barcelona Clinic Liver Cancer, BCLC B = patients with BCLC stage B plus those with BCLC stage C with low tumor burden (ETV <65 cm3 or ETB <4%), BCLC C = remaining patients with BCLC stage C with high tumor burden (ETV ≥65 cm3 or ETB ≥4%), ECOG = Eastern Cooperative Oncology Group, ETB = enhancing tumor burden, ETV = enhancing tumor volume.
*
Data are medians, with IQRs in parentheses.